This article summarizes the clinical features and molecular pathogenesis of medullary
thyroid cancer (MTC) and focuses on the current use of molecular, biochemical, and imaging …

The clinical management of patients with persistent or recurrent medullary thyroid carcinoma
(MTC) is still under debate, because these patients either have a long‐term survival, due to …

Medullary thyroid cancer: therapeutic targets and molecular... : Current Opinion in Oncology
Medullary thyroid cancer: therapeutic targets and molecular markers : Current Opinion in …

Although rare, medullary thyroid cancer (MTC) exemplifies the value that ever-expanding
knowledge of molecular pathways and mechanisms brings to managing challenging …

Medullary thyroid carcinoma is uncommon but accounts for approximately 4 to 5 per cent of
all thyroid cancers. Although most cases are sporadic, close to one-fourth of cases result …

Medullary thyroid cancer: early detection and novel treatmen... : Current Opinion in Oncology
Medullary thyroid cancer: early detection and novel treatments : Current Opinion in Oncology …

Background: Inherited and sporadic medullary thyroid cancer (MTC) is an uncommon and
challenging malignancy. The American Thyroid association (ATA) chose to create specific …

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor that accounts for 2-4% of
all thyroid cancers. All inherited MTC and approximately 50% of sporadic cases are driven …

Medullary thyroid cancer (MTC) is a relatively uncommon yet prognostically significant
thyroid cancer. Several recent advances in the biology and current or potential treatment of …

Medullary thyroid carcinoma (MTC) accounts for up to 8% of all thyroid cancers. Although
primary surgery is curative in the vast majority of patients treated at an early stage, disease …